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Abstract: Background. Since physical activity has a high impact on patients with type 1 diabetes and
the risk of hypoglycemia (low blood glucose levels) is significantly higher during and after physical
activities, an automatic method to provide a personalized recommendation is needed to improve
the blood glucose management and harness the benefits of physical activities. This paper aims to
reduce the risk of hypoglycemia and hyperglycemia (high blood glucose levels), and empowers
type 1 diabetes patients to make decisions regarding food choices connected with physical activities.
Methods. Traditional and Bayesian feedforward neural network models are developed to provide
accurate predictions of the blood glucose outcome and the risks of hyperglycemia and hypoglycemia
with uncertainty information. Using the proposed models, safe actions that minimize the risk
of both hypoglycemia and hyperglycemia are provided as food recommendations to the patient.
Results. The predicted blood glucose responses to the optimal and safe food recommendations are
significantly better and safer than by taking random food. Conclusions. Simulations conducted on the
state-of-the-art UVA/Padova simulator combined with Brenton’s physical activity model show that
the proposed methodology is safe and effective in managing blood glucose during and after physical
activities.
Keywords: type-1 diabetes; machine learning; feedforward neural networks; Bayesian neural
networks; physical activities
1. Introduction
Type 1 diabetes (T1D) is a chronic metabolic disorder characterized by elevated blood glucose
levels over a prolonged period, leading to long-term damage to the heart, kidneys, eyes, nerves,
and blood vessels. High blood glucose (hyperglycemia) in T1D is a consequence of the lack of insulin
produced by the pancreas so that T1D patients require external insulin administration to regulate
their blood glucose concentrations [1], while too much insulin dangerously reduces blood glucose
level (hypoglycemia).
Treatment of T1D mainly consists of either a basal-bolus insulin regimen, where patients take basal
insulin dose to regulate fasting blood glucose levels and insulin boluses around mealtimes to quickly
reduce the impact of carbohydrate intake, or through an insulin pump providing a continuous insulin
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infusion. The insulin pump infuses both regular basal insulin rate and meal boluses activated by the
user during food intake to avoid hyperglycemia [2]. In both therapies, the insulin is administered
subcutaneously in the fatty tissue just below the skin. In addition to the external insulin administration,
monitoring blood glucose levels is required and can be done via a continuous glucose monitor
(CGM) embedded in the subcutaneous tissue, or several times per day via manual finger-prick
measurements [3]. Finally, T1D patients in collaboration with a physician will design a treatment based
on individual patient needs. Insulin doses will be self-administered by the patients according to the
treatment plan and self-measured blood sugar concentrations. External insulin therapy aims to keep
the blood glucose concentrations within the normoglycemic range between 70 and 180 mg/dL [4,5].
Regular physical exercise has many proven health benefits and is therefore widely recommended
as part of a healthy lifestyle. However, exercise significantly alters glucose homeostasis in patients
with T1D. In addition, physical activities increase glucose uptake by muscles leading to a drop in
blood glucose concentration, which can reach the hazardous hypoglycemic values. Increased insulin
sensitivity, during and several hours or even days after the exercise [6], creates long-lasting effects on
daily activities of patients.
The common method for preventing hypoglycemia is to reduce insulin doses. However, the slow
absorption of insulin from the subcutaneous tissue and the physical limit of insulin reduction make this
method insufficient to prevent hypoglycemia. Additional to the insulin treatment, many T1D related
conditions can be mitigated by a nutrition therapy, which arises as an important solution to prevent,
manage and control diabetes, as well as relieve complications associated with T1D by adjusting the
quantity, quality and methods of nutrient intake [7]. Along with a healthy diet, physical activity plays
a vital role in diabetes treatment, producing multiple general and diabetes-specific health benefits [8].
Despite the evidenced benefits, many people are physically inactive [9], since exercise is a major source
of hypoglycemia in diabetic patients [10], and risk of hypoglycemia is a significant limiting factor of
blood glucose regulation in T1D patients [11]. For most diabetic people, exercise has far less adverse
health consequences than sedentary lifestyle [12].
Healthcare approaches change from the traditional relationship between providers and patients
to a paradigm that gives patients a crucial role in guiding their care [13]. The change emphasizes the
importance of self-management, which is considered a necessary part of chronic disease management
and secondary prevention [14], especially for diabetes patients. Evidence shows that supporting
patients to manage their health will improve clinical outcomes, reduce the economic burden,
and improve quality of life [14]. Food recommendation systems emerge as a new self-management
solution that can suggest the best diets according to patients’ health situation and preferences,
solving the physical activity paradigm while following a nutrition therapy for diabetic patients [15].
Among others, Phanich et al. [16] used a food-clustering analysis to propose a food recommendation
system for patients with diabetes, while Norouzi et al. [17] developed a smartphone application for
managing diabetic patient nutrition using artificial intelligence techniques. In [18], Lee et al. develop
a diabetic food recommendation agent that, according to a personal lifestyle and particular health
needs, can create a meal plan. Mohammed and Hagras [19] present a type-2 fuzzy logic-based diet
recommendation system to help achieve a healthy lifestyle to control diabetes. A complete systematic
review of nutrition recommendation systems with a focus on technical aspects can be found in [20].
Previous work from the authors has shown promising results for using machine learning techniques in
a food recommendation system, maintaining healthy blood glucose levels on a T1D simulator during
exercise [21].
The term machine learning is considered a large family of mathematical and statistical methods
that have historically focused on prediction [22]. With the development of new technology, a vast
amount of health-related data is continuously generated. However, data availability is varied among
various dimensions and quality. Machine learning and statistical techniques such as feedforward
neural networks and the Bayesian inferencing mechanism become powerful tools to understand and
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quantify data quality into uncertainties, which is a crucial step to make use of the increasingly available
data safely and effectively.
Due to the importance and clinical benefits of the diet in diabetes, different studies have been
conducted to develop diet recommendation systems to diabetes patients. Unlike [16,23], our work
focused on preventing the complications related to physical activity in type-1 diabetes patients,
alleviating the risks associated with doing exercise while having diabetes. Xie and Wang [24]
proposed a food recommendation system with a similar purpose using a Nonlinear Auto Regressive
Moving Average. However, the method did not provide a measurement of uncertainties in the data
and how to compensate for these uncertainties. In this work, we introduced a new technique for
food recommendation using Bayesian feedforward neural networks that can minimize the risk of
hypoglycemia and hyperglycemia during and after physical activities while improving blood glucose
regulation. We performed in-silico experiments, including the exercise model described in [25] on the
UVA/Padova simulator [26,27]. Our experiments demonstrate that the proposed food recommendation
system is able to reduce the risks of hypoglycemia and hyperglycemia while maintaining the blood
glucose levels in the healthy range during and after the exercise.
Structure of Paper
We describe the methods in Section 2, where we introduce the experimental setup, defined the
outcome and risk functions, and describe the models used to predict those functions. Section 3 presents
the results and discussion. Section 4 provides the clinical significance and limitations of the method.
In Section 5, we present concluding remarks and directions of possible future work.
2. Methods
The risk-averse food recommendation system presented in this paper used three criteria: the
blood glucose outcome, the risk of hypoglycemia, and the risk of hyperglycemia. Recommendations
were derived such that the risk of taking an action must be lower than a specified level and within a
measure of probabilistic confidence level, while maximizing the outcome. This section starts with a
description of the in-silico simulations used in the paper, followed by a formulation of the outcome and
risks. Finally, implementation of deterministic and Bayesian feedforward neural networks prediction
models are described.
2.1. In-Silico Simulation
In the simulation scenario used in the paper, the food recommendation is given before the
beginning of each exercise session for a virtual patient with no meal boluses associated with the
recommended amount of carbohydrates. During the experiments, the basal insulin dose was constant
and equal to the optimal value, which means the virtual patient stays at the healthy reference blood
glucose concentration BGre f = 108 mg/dL in steady-state. Training data was obtained by repeated
simulations from the blood glucose simulator under scenarios where a patient with T1D performs
physical exercises with the same intensity but consuming a different amount of food.
The Physical Activity Guidelines for Americans recommends adults do vigorous enough exercise
to raise their heart rate to 50–85% of their maximum heart rate, defined as 220 beats per minute minus
their age, during 75 to 150 min a week—values might vary for younger people [28]. The virtual patient
used in our simulations is 24 years old, with a maximum heart rate of 196 beats per minute and
recommended heart rate during exercise between 98 and 167 beats per minute, based on the guidelines
from the American Heart Association. The duration and intensity of physical activities are set to be
constant at 50 min and 157 beats per minute (80% of its maximum heart rate), respectively. In absence
of carbohydrate intake, a hypoglycemic excursion is induced as a consequence of the exercise session
setup. The virtual patient always eats at 15 min before the exercise starts to avoid the hypoglycemic
event. The outcome of each exercise is evaluated by measuring the average scores of the blood glucose
over the course of four hours starting at 15 min before the exercise (mealtime). The blood glucose is
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sampled every 5 min during the simulations, which is similar to the sampling time of common CGM
devices.
There exist mainly three physiological models in the T1D research field, namely the Bergman
(minimal) model [29], the Hovorka model [30] and the UVA/Padova model [26], see also [31].
The minimal model is a simplified model consisting of two equations describing the internal dynamics
of glucose and insulin and does not account for the significant delay involved in subcutaneous insulin
infusion. The Hovorka and the UVA/Padova models both include this delay as well as the delay in
the subcutaneous glucose measurement. In this work, we used the UVA/Padova model, since this is
the only computer simulator of the dynamics of the human metabolic glucose-insulin system which
is FDA approved as a substitute for the pre-clinical testing of certain control strategies in T1D [27].
An extension of the UVA/Padova model has been used in this paper where the effect of physical
activity is included [25].
The UVA/Padova model consists of seven internal compartments describing the dynamics
of glucose kinetics, insulin kinetics, glucagon kinetics and secretion, glucose rate of appearance,
endogenous glucose production, glucose utilization and renal excretion, while three external
compartments describe subcutaneous glucose, insulin and glucagon kinetics [27]. In addition,
a physical activity model was included in the glucose-utilization subsystem, modifying the
insulin-dependent utilization component to simulate exercise sessions describing changes in
glucose-insulin dynamics [25]. The original UVA/Padova simulator includes ten children patients,
ten adolescents patients, and ten adults patients, as well as one average child patient, one average
adolescent patient, and one average adult patient. In this work, we used the adult patient number
four during our experiments, since this patient presents acute hypoglycemia as a consequence of
our physical activity experimental setup. Finally, we use a CGM for glucose measurements during
our simulations, where the CGM sensor noise is generated based on the model and the parameters
determined by [32]. The non-Gaussian sensor noise is given by:
en = 0.8(en−1 + vn), n > 0 (1)
vn ∼ Niid(0, 1) (2)






with the initial condition e0 ∼ Niid(0, 1). Note that in the original model from [32], the error en
introduced in the sensor noise is multiplied by a factor of 0.7, while in this work we increased the
CGM noise multiplied the error en by a factor of 0.8, adding more uncertainty information to the
Bayesian feedforward neural network. The CGM sensor noise εn was added to the blood glucose
values obtained from the UVA/Padova simulator with physical activity. The numerical values used in
this paper for ξ, λ, γ and δ are shown in Table 1.






2.2. Outcome Function and Risk Definition
This subsection defines the outcome and risk functions for the designed food recommendation
system before physical activities for T1D patients. The blood glucose outcome is represented by the
average score assigned for the blood glucose levels during and after physical activities. The score was
calculated based on the asymmetric reward function previously introduced in [33], designed to reduce
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hypoglycemia while rewarding time spent in normoglycemia. The reward function is designed as a
piecewise smooth function and gives a strong negative reward for severe hypoglycemia, followed by
an exponentially decreasing negative reward for hypoglycemic events starting at severe hypoglycemia,
and negative reward when hyperglycemia occurs. Positive rewards from a symmetric linear function
are given for glucose values in normoglycemic range. To be specific, the function is given as:
r(BG) =

−10 : BG < BGhypo−
exp( log(19.157)BGhypo BG)− 19.157 : BG ∈ [BGhypo− , BGhypo]
1
36 BG− 2 : BG ∈ [BGhypo, BGre f ]
− 172 BG +
5
2 : BG ∈ [BGre f , BGhyper]
−5 : BG > BGhyper
, (4)
where BG is the current blood glucose value. The parameters of the reward function were selected
based on the guidelines as described in [33] and can be found in Table 2. A graphical representation of
the reward function is shown in Figure 1.
Table 2. Parameters of the reward function [33].
Parameter Description Value
BGre f Reference blood glucose 108 mg/dL
BGhyper Hyperglycemia blood glucose 180 mg/dL
BGhypo Hypoglycemia blood glucose 72 mg/dL
BGhypo− Severe hypoglycemia blood glucose 54 mg/dL



























Figure 1. The asymmetric reward function. Low blood glucose levels (a) are more penalized than (b)
high blood glucose levels.
In order to quantify the risks of hypo- and hyperglycemia, we used clinically defined low and
high blood glucose indices (LBGI and HBGI, respectively) as described in Clarke and Kovatchev [34],
which measure the frequency and extent of low and high blood glucose readings based on a














where BGi is the measurement i in mg/dL and n is the number of measurements during and after the
physical activity. The risk functions rl(BG) and rh(BG) are defined as follows:
rl(BG) = 10× f (BG)2 if f (BG) < 0 and 0 otherwise (6)
rh(BG) = 10× f (BG)2 if f (BG) > 0 and 0 otherwise (7)
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where
f (BG) = 1.509× [(ln(BG))1.084 − 5.381], (8)
and BG is the current blood glucose value.
2.3. Modelling of the Outcome, Risk and Uncertainties
This subsection describes the methods to predict the blood glucose outcome, the hypoglycemia
and the hyperglycemia risks of actions based on a predefined set of variables. Uncertainty estimation
using Bayesian techniques will be described with these methods.
The blood glucose outcome, hyperglycemia and hypoglycemia risks were predicted in this paper
by using a deterministic feedforward neural networks (FFNN) and two Bayesian feedforward neural
nerworks (BFNN) with the same structure. FFNN and BFNN are types of artificial neural networks
which are constructed by neurons organized into layers. The networks estimate the outcome and
risks based on inputs such as the intensity of physical activity, historical blood glucose and dietary
information (carbohydrate intake) before the physical activity. The structure of the deterministic
FFNN and the two BFNN implemented in this paper are similar and can be found in Figure 2. For
demonstration, we include only the food amount (carbohydrate intake) as the input for the networks.
It is assumed that other conditions are the same every time physical activity is conducted.
Information from the input also flows through hidden nodes, which are nonlinear functions of
the carbohydrate intake amount D:
hj = σ
(





where hj is the output value of the jth, j = 1, .., n hidden node, wj and bj are the weights and biases.
The function σ is a rectified linear unit activation function (ReLu):
σ(x) = max(0, x). (10)
The model output y, (either predicted risks or blood glucose outcome), is calculated from the
outputs of the hidden layers by a linear function:
ŷ = w(2)D + b(2), (11)
where w(2) and b(2) are the weight and bias for the output layer. The task of training the outcome
model is to find the optimal values of of w and b such that the following mean squared error (MSE)







(ŷi − yi)2, (12)
where N is the number of training samples, ŷi is the predicted value and yi is the actual blood glucose
score for each training sample i. Training of the outcome model was done using least square estimation
and implemented through the Pytorch library [35].
Two models were built to predict the hypoglycemia and hyperglycemia risks based on a Bayesian
feedforward neural network in order to capture the uncertainties in the risk prediction. The networks
have similar structure like the outcome prediction model with six hidden nodes. However, the weight
and bias of the hidden and output layers are represented by Gaussian distributions instead of discrete
numbers. The prior distribution of all the parameters were chosen to be normal distributions with
mean of zero and standard deviation of one. The task of training the hyperglycemia and hypoglycemia
models is to determine the posterior distribution for the weights and biases using Bayesian inference.
The posterior distribution was estimated by using the stochastic variational inference method [36] and
implemented with Pyro [37]. For each weight and bias z, a family of distributions is generated with
each distribution characterized by parameters θ. Then, an approximation of the posterior distribution
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pθ(z) is conducted by selecting from this family a distribution that is closest to the true posterior
p(z|y, x), where x and y are the training data set. The selection is conducted by finding the optimal set
of parameters θ that minimize the Kullback–Leibler divergence, which is a measurement of how two
probability distributions are different from each other [36,38]:
















+ log(p(y|x)) = −L(θ) + log(p(y|x)),
(13)












Figure 2. Structure of the feedforward neural networks for predicting the blood glucose outcome and
risks (a) blood glucose outcome (b) risks.
Since the Kullback–Leibler divergence is negative, the task of determining the posterior
distributions of all the weights and biases can be obtained by maximizing the ELBO by using the
stochastic gradient descend method, through variational inferencing [36].
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2.4. Validation
In order to validate the performances of the neural networks, parts of the data (20% for the FFNN
and 50% for the BFNN) were randomly selected for testing the model’s accuracy and performances.
By propagating the carbohydrate information in each sample set through the neural networks, the
prediction values are calculated and compared with the testing data. For the FFNN that is used to
blood glucose outcome, the distributions of the estimated risks and the actual risks are compared by
using the MSE (Equation (12)), which is also used as the validation criteria. For the BFNNs that are
used to estimate the hyperglycemia and hypoglycemia risks, the distributions of the estimated risks
and the actual risks are compared by using the ELBO criteria (Equation (14)). Since more data is need
for the ELBO than for the MSE calculation, a higher validation portion is assigned for the BFNN than
the FFNN.
3. Results and Discussion
By using data generated from the UVA/Padova simulator, the outcome and risk prediction models
were built based on gradient descend and the stochastic variational inference. Figure 3 shows the
MSE of the training and testing data during the training process of the feedforward neural networks.
Table 3 shows the final ELBO (defined by Equation (14)) of the Bayesian neural networks under
without and with noise in the CGM measurements. Figure 4 shows the training data and predictions
made by the models for different carbohydrate values without and with CGM noise, respectively.
The deterministic reward prediction is represented by the solid red line. The predicted risks with
90%-confidence intervals are represented by a green and a blue-shaded uncertainty bands in the figure,
correspondingly to the hypoglycemia and hyperglycemia risks, respectively.
It can be seen from Figure 3 and Table 3 that the prediction errors are higher when measurement
noise is introduced. Consequently, Figure 4 shows that the predicted risk uncertainty bands are wider
when there is measurement noise, indicating that the predicted risk cannot be accurately predicted
compared to nominal condition.
Based on the prediction models of the reward and risks, safe and optimal actions are derived as
shown in Table 4. Safe actions are defined as actions that have a 90% probability of the hypoglycemia
risk under 5 and the hyperglycemia risk under 7. The risk thresholds reflect that higher emphasis was
put on hypoglycemia due to the higher adverse effects of getting hypoglycemia. It can be seen that
the lower and upper bound for safe actions are tighter under noise conditions, since the risk models
capture the uncertainties and provide more conservative recommendations under more uncertain
condition. The optimal recommendation is chosen among the safe actions that maximize the blood
glucose outcome predicted by the deterministic feedforward neural network. Hence the value is the
same for both conditions when there is CGM noise and when there is no CGM noise.
Table 3. Evidence lower bound (ELBO) of the risk models for training and validation data.
Risk Training Validation
without Noise with Noise without Noise with Noise
Hyperglycemia 0.4198 0.0632 0.5340 0.0307
Hypoglycemia −0.4650 −0.7172 −0.3112 −1.0458
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(a) (b)
Figure 3. Training (solid blue line) and testing (orange dashed line) error without CGM measurement
noise (a) and with CGM measurement noise (b).
Figures 5 and 6 show different ranges of blood glucose when the patient follows the optimal
recommendation, consumes food within the safe recommendation actions, or takes food with
carbohydrate amounts between 0 and 200 g. The distribution of blood glucose measurement according
to food intakes at certain time points can also be seen in the figures. The results show that the range of
blood glucose responses to the optimal and safe actions are significantly better than the range of blood
glucose when any action can be selected. The blood glucose range is slightly narrower in the case with
CGM noise since the recommendation is more conservative in order to compensate for uncertainties in
the responses.
Table 4. Recommended actions (grams of carbohydrates).
Action Type No Noise with Noise
Safe lower 26.3 34.3
Safe upper 74.7 60.6
Optimal 50.2 50.2
(a) (b)
Figure 4. Training data (dots and cross), predicted outcome and risks under no CGM noise (a),
and CGM noise (b). Green and blue shaded uncertainty bands represent the 90% confident intervals
for hypoglycemia and hyperglycemia risks respectively.
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Figure 5. Blood glucose responses with no CGM noise in training data: (a) overtime as the effects of
all possible actions (blue shade), safe actions (green shade), and optimal action (red line) (b) over the
amount of carbohydrates at certain time points (red solid lines indicate safe actions).
Figure 6. Blood glucose responses with CGM noise in training data: (a) overtime as the effects of all
possible actions (blue shade), safe actions (green shade), and optimal action (red line) (b) over the
amount of carbohydrates at certain time points (red solid lines indicate safe actions).
4. Clinical Significance and Limitations
The methods presented in the paper demonstrate that a clinical decision support tool can be
built using machine learning. Uncertainties in the data can be estimated and recommendations are
provided with a statistically confident level. The tools have the potentials to be applicable in many
safety-critical applications beyond type-1 diabetes and contribute towards the development of safe
artificial intelligence. However, future efforts are needed to ensure the algorithms can be applied
beyond in sillico simulations.
As a demonstration of how risk-averse machine learning methods can be developed and how
the relationship between food intake and reward and risk can be visualized, only one variable
(carbohydrate) was chosen as the input of the neural networks. Future studies should incorporate
more variables that can affect blood glucose during and after physical activities such as previous
food intakes, insulin doses, blood glucose levels before exercises and heart rate. The uncertainties can
also be expanded to include other sources such as incorrect carbohydrate measurements, changes in
intensity of physical activities and blood glucose kinetics. It is also noted that more complex neural
networks require more data to obtain a satisfactory accuracy or performance, therefore, new methods
that can effectively reduce the dependence on a large dataset is needed. Propagation of uncertainty
analysis also contributes and make the methods more reliable. The current technique assumes that the
outputs of the Bayesian neural networks are Gaussian-distributed. New methods that can accurately
predict the output distribution will increase the accuracy of the prediction interval, and also the
recommendations provided to the patients.
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5. Conclusions
This paper provides a method to predict blood glucose outcome and risks associated with physical
activities. The prediction models were used to select safe and optimal food amounts for patients to
consume before physical activities. Simulation results show that the feedforward neural networks
accurately predicted the blood glucose outcome while the Bayesian neural networks effectively capture
the uncertainties due to measurement noise in the risk predictions. The blood glucose responses
to the safe and optimal actions are significantly better than random actions within the input range.
The results also present a potential direction for the future development of safe AI methods that are
not only effective but also minimizing potential risks to the patients.
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